Prescribing of clotrimazole-betamethasone dipropionate, a topical combination corticosteroid-antifungal product, for Medicare part D beneficiaries, United States, 2016-2022
During 2016-2022, Medicare part D beneficiaries filled 8,674,460 clotrimazole-betamethasone dipropionate prescriptions. Annual rates were stable (30.9 prescriptions/1,000 beneficiary-years in 2022, enough for one in every 33 beneficiaries). Diagnostic testing was infrequent, particularly among inter...
Saved in:
Main Authors: | Dustin W. Currie (Author), Avrom S. Caplan (Author), Kaitlin Benedict (Author), Kelly M. Hatfield (Author), Dallas J. Smith (Author), Shari R. Lipner (Author), Jeremy A.W. Gold (Author) |
---|---|
Format: | Book |
Published: |
Cambridge University Press,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
by: Efstratios Vakirlis, et al.
Published: (2008) -
Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination
by: Jalili A, et al.
Published: (2022) -
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
by: Anderko M, et al.
Published: (2019) -
Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review
by: Patel NU, et al.
Published: (2017) -
New Calcipotriol/Betamethasone Dipropionate Foam Formulation for the Treatment of Psoriasis: An Overview
by: Tiago Torres, et al.
Published: (2018)